Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs were updated April 1, 2025:
Effective May 1, 2025:
- Amifapridine
- ATTR Amyloidosis
- Casgevy
- Daybue
- Dry Eye Disease
- Duvyzat
- Elagolix/Reugolix
- Filspari
- GLP-1
- Hetlioz
- Hympavzi
- Interstitial Lung Disease
- Lyfgenia
- Risdiplam
- SA Oncology
- Spinraza
- Substrate Reduction Therapy
- Sunosi
- Wakix
- Weight Management
- Xhance
- Zolgensma
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions please contact your BCBSKS provider representative.